Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sutro Biopharma, Inc.
With
Children's Oncology Group
Innovative Therapies For Children with Cancer Consortium
This is a registrational international, multicenter, two-part open label Phase 1/2 trial in an extremely rare pediatric disease (around 17 new patients a year in US and 10 in EU). Part 1 randomizes subjects 1:1 to one of two luveltamab tazevibulin dose cohorts (1a and 1b). Part 2 further evaluates the safety and the efficacy of the selected dose. Subjects who achieve complete remission after two cycles of treatment may continue luveltamab tazevibulin as monotherapy, while non-responders at PI discretion may add luveltamab tazevibulin with standard of care (SOC) AML treatments. Luveltamab tazevibulin is given IV every two week as monotherapy and every 4 weeks when given with chemotherapy.
Age
0–12
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
AML with CBFA2T3::GLIS2 gene fusion centrally confirmed
Refractory or relapsed disease with ≥ 5% bone marrow involvement with leukemic blasts by morphology
Age \< 12 years.
Lansky performance of ≥ 50
Adequate organ functions
You may not be if
Active central nervous system (CNS) disease (CNS3)
Pre-existing clinically significant corneal disorders or constitutional diseases associated with an increased risk of AML treatment toxicities
Active or uncontrolled infections or other active severe intercurrent illnesses,
Prior treatment with a FOLR1- targeting ADCs or with ADCs that contain a tubulin inhibitor
History of allogeneic hematopoietic stem cell transplant or any organ transplant in the prior 84 days
Graft versus host disease (GVHD) of any grade or GVHD treatment with exception of low dose steroids